• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在一家保障型医院开展术中放射治疗项目:为服务不足的早期乳腺癌患者开展术中放射治疗项目的影响是什么?

Initiation of an Intraoperative Radiotherapy Program at a Safety net Hospital: What Is the Impact of an Intraoperative Radiotherapy Program in Underserved Patients With Early Breast Cancer?

机构信息

Department of Surgery, David Geffen School of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA.

Department of Radiology, Division of Radiation Oncology, Harbor-UCLA Medical Center, Torrance, CA, USA.

出版信息

Am Surg. 2021 May;87(5):833-838. doi: 10.1177/0003134820956351. Epub 2020 Nov 24.

DOI:10.1177/0003134820956351
PMID:33228433
Abstract

BACKGROUND

Intraoperative radiotherapy (IORT) can allow for single-dose radiation treatment following breast conservation therapy in low-risk patients with early breast cancer, in lieu of a traditional 6-week course of whole breast radiotherapy (WBRT). The objective of this study was to analyze the uptake and utilization of an IORT program in a safety-net hospital.

MATERIALS AND METHODS

A retrospective review was conducted for all patients who underwent IORT from September 2014 to June 2018. Patient demographics, tumor characteristics, and IORT outcomes were analyzed. The proportion of patients undergoing IORT were determined to assess utilization and uptake.

RESULTS

There were 27 female patients that received IORT, 23 (85.2%) of which required no further radiotherapy. Three (7.4%) patients had positive axillary lymph nodes and/or positive margins requiring subsequent WBRT. One patient (3.7%) developed an in-breast recurrence distant from the lumpectomy site 23 months after IORT. Ten patients (37.0%) developed a postoperative complication, including 5 seromas and 6 wound complications (superficial infections and/or wound necrosis). Overall, in the 46-month study period, IORT accounted for only 6.4% of 423 operations. Still, 27 of 29 (93.1%) patients who met eligibility criteria for IORT underwent the procedure.

DISCUSSION

Although IORT comprised only 6.4% of all cases due to higher rates of mastectomy rates and advanced disease in our population, there was a high uptake of IORT among patients who met eligibility criteria for the procedure. Major complication rates of IORT were low, and most patients successfully completed radiotherapy in 1 intraoperative dose.

摘要

背景

对于早期乳腺癌低危患者,保乳术后可采用术中放疗(IORT)进行单次剂量放疗,而无需进行传统的 6 周全乳放疗(WBRT)。本研究旨在分析一家社区医院 IORT 项目的应用情况。

材料与方法

对 2014 年 9 月至 2018 年 6 月期间所有接受 IORT 的患者进行回顾性分析。分析患者的人口统计学、肿瘤特征和 IORT 结果。通过确定接受 IORT 的患者比例来评估其利用率和应用情况。

结果

共 27 例女性患者接受 IORT,其中 23 例(85.2%)无需进一步放疗。3 例(7.4%)患者腋窝淋巴结阳性和/或切缘阳性,需行后续 WBRT。1 例(3.7%)患者在 IORT 后 23 个月发生了距保乳手术部位较远的局部复发。10 例患者(37.0%)发生术后并发症,包括 5 例血清肿和 6 例伤口并发症(浅表感染和/或伤口坏死)。在 46 个月的研究期间,IORT 仅占 423 例手术的 6.4%。尽管如此,在符合 IORT 适应证的 29 例患者中,有 27 例接受了该手术。

讨论

尽管由于我们人群中乳房切除术率较高且疾病进展较晚,IORT 占所有病例的比例仅为 6.4%,但符合 IORT 适应证的患者对 IORT 的接受程度较高。IORT 的主要并发症发生率较低,大多数患者成功地在单次术中剂量内完成了放疗。

相似文献

1
Initiation of an Intraoperative Radiotherapy Program at a Safety net Hospital: What Is the Impact of an Intraoperative Radiotherapy Program in Underserved Patients With Early Breast Cancer?在一家保障型医院开展术中放射治疗项目:为服务不足的早期乳腺癌患者开展术中放射治疗项目的影响是什么?
Am Surg. 2021 May;87(5):833-838. doi: 10.1177/0003134820956351. Epub 2020 Nov 24.
2
Frequency of whole breast radiation therapy after intraoperative radiation therapy due to criteria identified by lumpectomy.根据乳房肿瘤切除术确定的标准,术中放疗后全乳放疗的频率。
Brachytherapy. 2017 Jan-Feb;16(1):174-180. doi: 10.1016/j.brachy.2016.09.012. Epub 2016 Nov 2.
3
Redefining Eligibility by Analyzing Canceled Intraoperative Radiotherapy as a Boost for Patients Undergoing Breast-Conserving Treatment.重新定义资格:分析因术中放射治疗取消而作为保乳治疗患者辅助治疗的情况。
Ann Surg Oncol. 2019 Dec;26(13):4294-4301. doi: 10.1245/s10434-019-07819-5. Epub 2019 Sep 13.
4
Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial.保乳术后单次剂量靶向术中放疗(TARGIT-IORT)治疗早期乳腺癌的长期生存和局部控制结果:TARGIT-A 随机临床试验。
BMJ. 2020 Aug 19;370:m2836. doi: 10.1136/bmj.m2836.
5
Factors predictive of failure to complete planned intraoperative breast radiation using the intrabeam® system.使用Intrabeam®系统预测未能完成计划中的术中乳腺放疗的因素。
J Surg Oncol. 2016 Dec;114(8):930-932. doi: 10.1002/jso.24473. Epub 2016 Nov 11.
6
Targeted Intraoperative Radiotherapy for the Management of Ductal Carcinoma In Situ of the Breast.靶向术中放疗用于治疗乳腺导管原位癌
Breast J. 2016 Jan-Feb;22(1):63-74. doi: 10.1111/tbj.12516. Epub 2015 Nov 3.
7
Toxicity and cosmetic outcomes after treatment with a novel form of breast IORT.新型乳房术中放射治疗的毒性和美容效果。
Brachytherapy. 2020 Sep-Oct;19(5):679-684. doi: 10.1016/j.brachy.2020.05.002. Epub 2020 Jun 20.
8
Intraoperative radiotherapy (IORT) is an option for patients with localized breast recurrences after previous external-beam radiotherapy.术中放疗(IORT)是既往接受过外照射放疗后出现局部乳腺复发患者的一种选择。
BMC Cancer. 2007 Sep 14;7:178. doi: 10.1186/1471-2407-7-178.
9
Single institute experience of intraoperative radiation therapy in early-stage breast cancer.单中心经验:术中放疗在早期乳腺癌中的应用。
Medicine (Baltimore). 2021 Nov 19;100(46):e27842. doi: 10.1097/MD.0000000000027842.
10
Oncoplastic breast-conserving therapy and intraoperative radiotherapy for management of carcinoma in situ of the breast: A single-center experience.保乳术联合术中放疗治疗乳腺原位癌:单中心经验。
Breast J. 2020 Dec;26(12):2391-2394. doi: 10.1111/tbj.14093. Epub 2020 Dec 6.

引用本文的文献

1
Prospects and Disadvantages of Intraoperative Radiotherapy: A Systematic Review.术中放疗的前景与弊端:一项系统综述
Asian Pac J Cancer Prev. 2025 May 1;26(5):1507-1517. doi: 10.31557/APJCP.2025.26.5.1507.
2
The Role of Safety-Net Hospitals in Reducing Disparities in Breast Cancer Care.安全网医院在减少乳腺癌护理差异方面的作用。
Ann Surg Oncol. 2022 Mar 31. doi: 10.1245/s10434-022-11576-3.